Equillium (EQ) Net Cash Flow Growth (3y) (2021 - 2026)
Equillium (EQ) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-13.44% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Equillium |
293.17 Mn |
232.78 Mn |
- |
42.56% |
| Date | Value |
|---|
| Mar 31, 2026 |
42.56% |
| Dec 31, 2025 |
-27.78% |
| Sep 30, 2025 |
123.62% |
| Jun 30, 2025 |
-5.66% |
| Mar 31, 2025 |
47.04% |
| Dec 31, 2024 |
28.13% |
| Sep 30, 2024 |
6.14% |
| Jun 30, 2024 |
-26.56% |
| Mar 31, 2024 |
-34.49% |
| Dec 31, 2023 |
23.88% |
| Sep 30, 2023 |
-29.47% |
| Jun 30, 2023 |
-30.46% |
| Mar 31, 2023 |
-88.24% |
| Dec 31, 2022 |
62.67% |
| Sep 30, 2022 |
33.76% |
| Jun 30, 2022 |
-58.74% |
| Mar 31, 2022 |
-50.22% |
| Dec 31, 2021 |
-46.42% |
| Sep 30, 2021 |
61.46% |
| Jun 30, 2021 |
176.40% |
